Back to Journals » OncoTargets and Therapy » Volume 10

miR-762 can negatively regulate menin in ovarian cancer

Authors Hou R, Yang Z, Wang S, Chu D, Liu Q, Liu J, Jiang L

Received 16 November 2016

Accepted for publication 10 February 2017

Published 12 April 2017 Volume 2017:10 Pages 2127—2137

DOI https://doi.org/10.2147/OTT.S127872

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Chiung-Kuei Huang

Rui Hou,1 Zhuo Yang,1 ShiZhuo Wang,1 DaMing Chu,1 Qifang Liu,1 Jia Liu,1 Luo Jiang2

1Department of Obstetrics and Gynecology, 2Department of Ultrasound, Shengjing Hospital Affiliated to China Medical University, Shenyang, People’s Republic of China

Abstract:
Ovarian cancer accounts for the major part of the mortality attributable to female reproductive system malignant tumors worldwide. Recently, the incidence of ovarian cancer has been increasing annually, and there remains a lack of suitable treatment methods that can significantly improve the 5-year survival rates of patients. Therefore, it is necessary to identify more effective treatments for ovarian cancer. It is established that microRNAs (miRNAs) have important roles in the diagnosis and treatment of ovarian cancer and a specific miRNA, miR-762, can promote the development of a variety of tumors. Menin is encoded by MEN1, a tumor suppressor gene, that is usually downregulated in ovarian cancer. In this study, we evaluated the expression levels of miR-762 and menin in ovarian cancer tissues and demonstrated that they were correlated. In addition, we found that miR-762 can downregulate the expression of menin through a binding site in its 3'-UTR and consequently upregulate the Wnt cell signaling pathway to promote the development of ovarian cancer. These results indicate that miR-762 is a promising potential target for the treatment of ovarian cancer.

Keywords: miR-762, menin, ovarian cancer
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]